Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/a-phase-i-study-of-obatoclax-mesylate-a-bcl-2-antagonist-plus-j0WEPe7Yg6
References (27)
-
S. O'brien, D. Claxton, M. Crump, S. Faderl, T. Kipps, M. Keating, J. Viallet, B. Cheson (2009)
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.Blood, 113 2
-
Jerry Adams, S. Cory (2007)
The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 26
-
Paula Hauck, B. Chao, J. Litz, G. Krystal (2009)
Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737Molecular Cancer Therapeutics, 8
-
A. Schimmer, S. O'Brien, H. Kantarjian, J. Brandwein, B. Cheson, M. Minden, K. Yee, F. Ravandi, F. Giles, A. Schuh, Vikas Gupta, M. Andreeff, C. Koller, Hong Chang, S. Kamel‐Reid, M. Berger, J. Viallet, G. Borthakur (2008)
A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic MalignanciesClinical Cancer Research, 14
-
Jiannong Li, J. Viallet, E. Haura (2008)
A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cellsCancer Chemotherapy and Pharmacology, 61
-
A. Chiappori, M. Schreeder, M. Moezi, J. Stephenson, J. Blakely, R. Salgia, Q. Chu, S. Malik, M. Modiano, M. Berger (2009)
A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
D. Zhang, J. Armstrong (2007)
Bax and the mitochondrial permeability transition cooperate in the release of cytochrome c during endoplasmic reticulum-stress-induced apoptosisCell Death and Differentiation, 14
-
P. Galán, G. Roué, N. Villamor, E. Campo, D. Colomer (2005)
The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib.Blood, 106
-
R. Huber, M. Reck, H. Gosse, J. Pawel, J. Mezger, J. Saal, R. Kleinschmidt, C. Steppert, H. Steppling (2006)
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancerEuropean Respiratory Journal, 27
-
Shi‐Xu Jiang, Yuichi Sato, S. Kuwao, T. Kameya (1995)
Expression of bcl‐2 oncogene protein is prevalent in small cell lung carcinomasThe Journal of Pathology, 177
-
M. Higashiyama, O. Doi, K. Kodama, H. Yokouchi, R. Tateishi (1996)
Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 17 6
-
Haichao Zhang, Paul Nimmer, S. Tahir, Jun Chen, R. Fryer, K. Hahn, L. Iciek, S. Morgan, M. Nasarre, R. Nelson, L. Preusser, G. Reinhart, Morey Smith, S. Rosenberg, S. Elmore, Chris Tse (2007)
Bcl-2 family proteins are essential for platelet survivalCell Death and Differentiation, 14
-
K. Mason, M. Carpinelli, J. Fletcher, J. Collinge, Adrienne Hilton, S. Ellis, Priscilla Kelly, P. Ekert, D. Metcalf, A. Roberts, D. Huang, B. Kile (2007)
Programmed Anuclear Cell Death Delimits Platelet Life SpanCell, 128
-
Annemarie Ziegler, G. Luedke, Rolf Stahel, U. Zangemeister‐Wittke, Doriano Fabbro, K. Altmann (1997)
Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.Journal of the National Cancer Institute, 89 14
-
E. Fokkema, E. Vries, H. Groen, C. Meijer, W. Timens (2003)
Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatmentVirchows Archiv, 442
-
Young Kim, L. Girard, Craig Giacomini, Pei Wang, T. Hernandez-Boussard, R. Tibshirani, J. Minna, J. Pollack (2006)
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplificationOncogene, 25
-
Chris Tse, A. Shoemaker, Jessica Adickes, Mark Anderson, Jun Chen, Sha Jin, Eric Johnson, K. Marsh, M. Mitten, Paul Nimmer, Lisa Roberts, S. Tahir, Yu Xiao, Xiufen Yang, Haichao Zhang, S. Fesik, S. Rosenberg, S. Elmore (2008)
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.Cancer research, 68 9
-
R. Koschel, R. Huber, U. Gatzemeier, H. Gosse, J. Pawel, D. Hruska, J. Mezger, J. Saal (2000)
Topotecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapyLung Cancer, 29
-
U. Sartorius, P. Krammer (2002)
Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell linesInternational Journal of Cancer, 97
-
U. Zangemeister‐Wittke, T. Schenker, G. Luedke, R. Stahel (1998)
Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.British Journal of Cancer, 78
-
Wyndham Wilson, O. O'Connor, Andrew Roberts, M. Czuczman, Jennifer Brown, Hao Xiong, Y. Chiu, A. Krivoshik, S. Enschede, R. Humerickhouse (2016)
ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
M. Nguyen, R. Marcellus, A. Roulston, M. Watson, L. Serfass, S. Madiraju, D. Goulet, J. Viallet, L. Bélec, Xavier Billot, Stéphane Acoca, E. Purisima, A. Wiegmans, L. Cluse, R. Johnstone, P. Beauparlant, G. Shore (2007)
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisProceedings of the National Academy of Sciences, 104
-
R. Perez-soler, B. Glisson, Jin Lee, F. Fossella, W. Murphy, D. Shin, W. Hong (1996)
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 10
-
A. Roberts, W. Wilson, L. Gandhi, O. O’Connor, C. Rudin, J. Brown, H. Xiong, Y. Chiu, S. Enschede, A. Krivoshik (2009)
Ongoing phase I studies of ABT-263: Mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
S. Fesik (2005)
Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 5
-
J. Eckardt, J. Pawel, Z. Pápai, A. Tomova, V. Tzekova, T. Crofts, S. Brannon, P. Wissel, G. Ross (2006)
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
-
Wei Hu, J. Kavanagh (2003)
Anticancer therapy targeting the apoptotic pathway.The Lancet. Oncology, 4 12
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Springer-Verlag
- Subject
- Medicine & Public Health; Oncology; Cancer Research ; Pharmacology/Toxicology
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- DOI
- 10.1007/s00280-010-1265-5
- pmid
- 20165849
- Publisher site
- See Article on Publisher Site
Abstract
Obatoclax mesylate administered at 14 mg/m 2 IV on days 1 and 3 is safe and well tolerated when given in combination with topotecan 1.25 mg/m 2 IV on days 1–5 of an every 3-week cycle. A phase II trial to assess the efficacy of this combination for patients with relapsed SCLC is currently accruing patients.
Journal
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Nov 1, 2010